Compare Msci Inc (MSCI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Zimmer Biomet Holdings Inc — how do they compare? Msci Inc trades at $562.98 (market cap $45.51B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Msci Inc is far larger — about 2.6× Zimmer Biomet Holdings Inc's market cap, and Msci Inc pays the higher dividend (1.31%). Which is the better fit depends on your goals.
| MSCI | ZBH | |
|---|---|---|
Market Cap | $45.51B | $17.36B |
Sector | Financials | Health |
52-Week High | $643.83 | $107.71 |
52-Week Low | $511.84 | $79.58 |
Enterprise Value | $51.67B | $24.40B |
Dividend Yield | 1.31% | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
